P53, MDM-2, BAX and BCL-2 and drug resistance in chronic lymphocytic leukemia.

@article{Johnston1997P53MB,
  title={P53, MDM-2, BAX and BCL-2 and drug resistance in chronic lymphocytic leukemia.},
  author={James Blain Johnston and Paul Joseph Daeninck and Linda Verburg and K Lee and Gill Williams and Lyonel G. Israels and Michael R A Mowat and Asher Begleiter},
  journal={Leukemia & lymphoma},
  year={1997},
  volume={26 5-6},
  pages={435-49}
}
Most antitumor agents exert their cytotoxic effect through the induction of apoptosis, and this process may be mediated through an elevation in p53 protein, with a subsequent increase in bax and decrease in bcl-2. p53 also increases mdm-2 expression and mdm-2 may then bind and inactivate p53. Cells from 31 patients with chronic lymphocytic leukemia (CLL) were treated in vitro with 2-chlorodeoxyadenosine (CdA), arabinosyl-2-fluoroadenine (F-ara-A), or chlorambucil (CLB) and drug sensitivity… CONTINUE READING
32 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 32 extracted citations

Similar Papers

Loading similar papers…